Early trial tests new combo for tough cervical cancers
NCT ID NCT03298893
Summary
This study tested the safety of adding a new immunotherapy drug called nivolumab to the standard treatment of radiation and chemotherapy for women with locally advanced cervical cancer. It involved 21 patients and aimed to see if this combination was safe and might be more effective. After the main treatment, patients received additional nivolumab for up to six months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hopital Européen Georges Pompidou
Paris, 75015, France
-
Institut Curie
Paris, 75005, France
-
Institut Curie Hopital René Huguenin
Saint-Cloud, 9220, France
Conditions
Explore the condition pages connected to this study.